BHST Company Profile and Key Details

BioHarvest Sciences Inc. Common Stock (NASDAQ:BHST) closed at $2.76 USD, losing -$0.10 (-3.50%) from the previous close of $2.86. The stock is currently trading near its 52-week low $2.75 and $12.80. With a market capitalization of about $47.82 million, BioHarvest Sciences Inc. Common Stock is classified as a micro-cap and shows higher-than-market volatility (beta ~1.38). Key stats such as the average daily volume over the past year has been around 29.09 thousand shares, trading with heavier-than-usual volume. Headquartered in Vancouver, BC, BioHarvest Sciences Inc. Common Stock operates in the Basic Materials sector and the Agricultural Inputs industry. Led by CEO Ilan Sobel, the company employs approximately 87 people and listed since January 08, 2021. BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals.

Short-term trend indicators are bullishly aligned (SMA20 0.86%, SMA50 -5.2%, SMA200 -34.37%). The stock’s 14-day RSI is 47.22 (neutral), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -62.73% below its high and over 11.71% above its low. Average 10-day trading volume of 40.67 thousand shares is slightly above the 3-month average of 30.58 thousand, indicating heightened recent market interest.

BioHarvest Sciences Inc. Common Stock trades at a P/E ratio of -4.61, slightly below the S&P 500 average, with a price-to-sales ratio of 1.41 and a price-to-book ratio of 2.82 suggesting the stock is closer to book value. The P/FCF stands at -5.09, also below market averages.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

BioHarvest Sciences Inc. Common Stock generated EPS of -$0.69 over the past year. Five-year average earnings growth is 45.0%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 262.32% upside. The low target suggests 262.32% downside. The mean target is $10.00. This offers 262.32% upside. BioHarvest Sciences Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by -9.09%. The prior quarter beat by -4.76%. Over the last six quarters, Apple has recorded several small beats. These include 41.67% in March 31, 2025.

BioHarvest Sciences Inc. Common Stock has 22.67 million shares outstanding. The public float is 17.82 million shares, elevated short interest at 0.37% of float. This equals 71.51 thousand shares. The short ratio is 1.81 days. Institutional investors hold 0.84% of the float. Insiders own 25.97%.

Our AI price prediction model suggests that BioHarvest Sciences Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.33%, with price expected at $2.53 by July 22, 2026, within a range of $2.33 to $2.71 3-Month Outlook: Projected rise of 12.68%, reaching $3.11 by October 06, 2026, with a range of $2.77 to $3.38. 1-Year Outlook: Projected loss of -14.86%, with price at $2.35 by July 08, 2027, within a range of $0.00 to $1.87.

BioHarvest Sciences Inc. Common Stock (NASDAQ:BHST) shares are flat -7.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BioHarvest Sciences Inc. Common Stock trading at a premium to the broader market with a P/E of -4.61. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.80, suggesting 363.77% upside. Our AI forecast model points to short-term weakness (-8.33% over two weeks), a medium-term rise (12.68% over three months), and a longer-term loss (-14.86% over one year), with expected trading ranges indicating moderate volatility.